RFS Archives - Agendia

Anthracycline Plus Chemo Associated With Improved RFS in MP High-2–Risk, HR+/HER2– Early Breast Cancer
Gallery
Anthracycline Plus Chemo Associated With Improved RFS in MP High-2–Risk, HR+/HER2– Early Breast Cancer

News

Anthracycline Plus Chemo Associated With Improved RFS in MP High-2–Risk, HR+/HER2– Early Breast Cancer

By Ryan Scott June 1, 2024 Key Takeaways Patients Read More

Karen Guzdzial2024-08-07T10:51:45-04:00June 7th, 2024|News|

Improved RFS Seen with Anthracycline Plus Chemo in MP High-2–Risk, HR+/HER2– Early Breast Cancer
Gallery
Improved RFS Seen with Anthracycline Plus Chemo in MP High-2–Risk, HR+/HER2– Early Breast Cancer

News

Improved RFS Seen with Anthracycline Plus Chemo in MP High-2–Risk, HR+/HER2– Early Breast Cancer

By Ryan Scott June 1, 2024 A lower risk of Read More

Karen Guzdzial2024-08-07T10:54:51-04:00June 7th, 2024|News|

Agendia precision oncology

Quick Links

Our Tests
Resources
Landmark Trials
Order A Test
For Patients
Newsroom

Legal

Privacy Policy
Legal & Compliance
Terms & Conditions
Licenses & Accreditations
Code of Conduct

Contact

For the US, Puerto Rico, Canada
and South America
Agendia Inc. USA, 22 Morgan, Irvine, CA 92618
(888) 321-2732
customercare@agendia.com

For outside the Americas
Agendia NV, Radarweg 60, 1043 NT Amsterdam, The Netherlands
+31 (0)20 462 1510
customerservice@agendia.com

©2024 Agendia. All rights reserved. MammaPrint and Blueprint are registered trademarks of Agendia, Inc.